European Commission approval for Verquvo to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction – Bayer + Merck Inc.
Merck Inc., has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). In the… read more.
